Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma



Status:Active, not recruiting
Conditions:Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any - 21
Updated:3/17/2019
Start Date:February 4, 2013

Use our guide to learn which trials are right for you!

A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma

This phase I trial studies the side effects and best dose of lenalidomide when given together
with dinutuximab with or without isotretinoin in treating younger patients with neuroblastoma
that does not respond to treatment or that has come back. Drugs used in chemotherapy, such as
lenalidomide and isotretinoin, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Monoclonal antibodies, such as dinutuximab, may interfere with the ability of
tumor cells to grow and spread. Giving more than one drug (combination chemotherapy) together
with dinutuximab therapy may kill more tumor cells.

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of
lenalidomide in combination with fixed doses of dinutuximab (ch14.18) and isotretinoin given
to children with refractory or recurrent neuroblastoma.

II. To define the toxicities of lenalidomide administered in combination with ch14.18 and
isotretinoin.

III. To describe the differences in immune function modulation between "low" versus "high"
dose lenalidomide given with ch14.18 and isotretinoin.

SECONDARY OBJECTIVES:

I. To determine the pharmacokinetics of lenalidomide given in this combination regimen.

II. To determine the steady state pharmacokinetics of isotretinoin (day 28, course one) given
in combination with lenalidomide.

III. To measure peak and trough levels of ch14.18 in patients receiving lenalidomide and to
compare to historical controls of patients receiving ch14.18 in combination with interleukin
2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

IV. To describe the immunological effects of lenalidomide (T cells, natural killer [NK]
cells, monocytes, cytokines, chemokines) within this three drug regimen.

V. To define the incidence and titers of human anti-chimeric antibody (HACA) on this regimen.

VI. To describe, within the context of a phase I study, the response rate to lenalidomide
combined with ch14.18 and isotretinoin in patients with recurrent/refractory neuroblastoma.

VII. To summarize, within the context of a phase I study, the event-free survival of patients
with recurrent/refractory neuroblastoma or in complete response (CR) after progressing, and
who are treated with lenalidomide combined with ch14.18 and isotretinoin.

VIII. To determine, within the context of a phase I study, if killer-cell immunoglobulin-like
receptor (KIR) receptor-ligand mismatch or specific Fc gamma receptor (Fc gamma R) alleles
are associated with anti-tumor response.

IX. To quantify neuroblastoma tumor cell "load" using a 5-gene TaqMan Low Density Array
(TLDA) assay in peripheral blood at study entry, following, with each disease evaluation and
at end of therapy and bone marrow at study entry, with each response evaluation when bone
marrow is sampled, and at end of therapy.

X. To compare the toxicities of this regimen with the historical toxicity data from the
Children's Oncology Group (COG) ANBL0032 and ANBL0931 studies of ch14.18 with IL-2, GM-CSF
and isotretinoin.

XI. To describe the tolerability and ability to give full doses of ch14.18 and lenalidomide
over extended periods of time, i.e. in courses 6-12.

OUTLINE: This is a dose-escalation study of lenalidomide.

Patients receive lenalidomide orally (PO) once daily (QD) on days 1-21, dinutuximab
intravenously (IV) over 10 hours on days 8-11, and isotretinoin PO twice daily (BID) on days
15-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease
progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.

Inclusion Criteria:

- Patients must have a diagnosis of neuroblastoma either by histologic verification of
neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased
urinary catecholamines

- Patients must have high-risk neuroblastoma

- Patients must have at least ONE of the following:

- Recurrent/progressive disease at any time prior to enrollment - regardless of
response to frontline therapy

- Refractory disease: persistent sites of disease (after less than a partial
response to frontline therapy, following a minimum of 4 cycles of induction
therapy) AND patient has never had a relapse/progression

- Persistent disease: persistent disease after achieving at least a partial
response to frontline therapy after a minimum of 4 cycles of induction therapy
and patient has never had a relapse/progression

- Patients must have at least ONE of the following (lesions may have received prior
radiation therapy as long as they meet the other criteria listed below):

- Bone disease

- At least one metaiodobenzylguanidine (MIBG) avid bone site or diffuse MIBG
uptake

- For recurrent/progressive or refractory disease a biopsy is not
required regardless of number of MIBG avid lesions

- For persistent disease, if patient has only 1 or 2 MIBG avid lesions OR
a Curie score of 1-2, then biopsy confirmation of neuroblastoma and/or
ganglioneuroblastoma in at least one site present at the time of
enrollment (bone marrow, bone, or soft tissue) is required to be
obtained at any time point prior to enrollment and two weeks subsequent
to most recent prior therapy; if a patient has 3 or more MIBG avid
lesions OR a Curie score of >= 3 then no biopsy is required for
eligibility

- If a tumor is known to be MIBG non-avid, then a patient must have at least
one fludeoxyglucose (FDG)-positron emission tomography (PET) avid bone site
present at the time of enrollment with biopsy confirmation of neuroblastoma
and/or ganglioneuroblastoma obtained at any time prior to enrollment and two
weeks subsequent to most recent prior therapy

- Any amount of neuroblastoma tumor cells in the bone marrow based on routine
morphology (with or without immunocytochemistry) in at least one sample from
bilateral aspirates and biopsies

- At least one soft tissue lesion that meets the criteria for a TARGET lesion as
defined by:

- SIZE: Lesion can be accurately measured in at least one dimension with a
longest diameter >= 10 mm, or for lymph nodes >= 15 mm on short axis;
lesions meeting size criteria will be considered measurable

- In addition to size, a lesion needs to meet ONE of the following criteria:

- MIBG avid; for patients with persistent disease only: if a patient has
only 1 or 2 MIBG avid lesions OR a Curie score of 1-2, then biopsy
confirmation of neuroblastoma and/or ganglioneuroblastoma in at least
one site present at time of enrollment (either bone marrow, bone and/or
soft tissue) is required to be obtained at any time point prior to
enrollment and at least two weeks subsequent to most recent prior
therapy; if a patient has 3 or more MIBG avid lesions OR a Curie score
of >= 3 then no biopsy is required for eligibility

- FDG-PET avid (only if tumor is known to be MIBG non-avid); these
patients must have had a biopsy confirming neuroblastoma and/or
ganglioneuroblastoma in at least one FDG-PET avid site present at the
time of enrollment done prior to enrollment and at least two weeks
subsequent to the most recent prior therapy

- Non-avid lesion (both MIBG and FDG-PET non-avid); these patients must
have had a biopsy confirming neuroblastoma and/or ganglioneuroblastoma
in at least one non-avid lesion present at the time of enrollment done
prior to enrollment and at least two weeks subsequent to the most
recent prior therapy

- Patients with prior progressive disease who do not meet criteria above, are eligible
as long as they have not been off treatment for > 3 months prior to enrollment on NANT
2011-04

- Patients must have a life expectancy of at least 6 weeks

- Lansky (=< 16 years) or Karnofsky (> 16 years) score of at least 50

- Patients must have fully recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, or radiotherapy prior to study enrollment

- Patients must not have received the therapies indicated below for the specified time
period prior to the first day of administration of protocol therapy on this study

- Myelosuppressive chemotherapy: must have received last dose at least 2 weeks
prior to protocol therapy; this includes cytotoxic agents given on a low dose
metronomic regimen

- Biologic (anti-neoplastic agent) (includes retinoids): must have received last
dose at least 7 days prior to protocol therapy

- Monoclonal antibodies: must have received last dose at least 7 days or 3
half-lives, whichever is longer, prior to protocol therapy

- Radiation:

- Patients must not have received radiation (small port) for a minimum of two weeks
prior to protocol therapy

- Except for patients with a history of progressive disease, patients whose only
site(s) of disease have been radiated are eligible if at least one lesion meets
at least one of the criteria listed in sites of disease above

- A minimum of 12 weeks prior to start of protocol therapy is required following
large field radiation therapy (i.e. total body irradiation, craniospinal, whole
abdominal, total lung, > 50% marrow space)

- A minimum of 6 weeks must have elapsed prior to start of protocol therapy for
other substantial bone marrow radiation

- Stem Cell Transplant (SCT):

- Patients are eligible 6 weeks after date of autologous stem cell infusion
following myeloablative therapy (timed from first day of protocol therapy)

- Patients are not eligible post allogeneic stem cell transplant

- Patients who have received an autologous stem cell infusion to support
non-myeloablative therapy (such as 131 iodine [I]-MIBG) are eligible at any time
as long as they meet the other criteria for eligibility

- A minimum of 6 weeks must have elapsed after 131I-MIBG therapy prior to start of
protocol therapy

- Prior anti-disialoganglioside (GD2) antibody, isotretinoin, or lenalidomide therapy:

- Patients who have received prior anti-GD2 antibody therapy are eligible if they
did not have tumor relapse/progression while receiving this therapy

- Patients who have received either isotretinoin or lenalidomide are eligible, but
not if they have received the two agents concomitantly

- All cytokines or hematopoietic growth factors must be discontinued a minimum of 7 days
prior to protocol therapy

- Patients must not be receiving any other anti-cancer agents or radiotherapy at the
time of study entry or while on study

- Absolute phagocyte count (APC = neutrophils and monocytes): >= 1000/mm^3

- Absolute neutrophil count: >= 750/mm^3

- Platelet count: >= 50,000/mm^3, transfusion independent (no platelet transfusions
within 1 week)

- Hemoglobin >= 8.0 (may transfuse)

- Patients with known bone marrow metastatic disease will be eligible for study as long
as they meet hematologic function criteria; patients with marrow disease are not
evaluable for hematologic toxicity

- Age-adjusted serum creatinine =< 1.5 x normal for age or creatinine clearance or
glomerular filtration rate (GFR) >= 60 cc/min/1.73 m^2

- Age 1 month to < 6 months: 0.4 mg/dL for males and 0.4 mg/dL for females

- Age 6 months to < 1 year: 0.5 mg/dL for males and 0.5 mg/dL for females

- Age 1 to < 2 years: 0.6 mg/dL for males and 0.6 mg/dL for females

- Age 2 to < 6 years: 0.8 mg/dL for males and 0.8 mg/dL for females

- Age 6 to < 10 years: 1.0 mg/dL for males and 1.0 mg/dL for females

- Age 10 to < 13 years: 1.2 mg/dL for males and 1.2 mg/dL for females

- Age 13 to < 16 years: 1.5 mg/dL for males and 1.4 mg/dL for females

- Age >= 16 years: 1.7 mg/dL for males and 1.4 mg/dL for females

- =< grade 2 hematuria (criteria applicable only for dose levels that include
isotretinoin) and =< grade 2 proteinuria

- Total bilirubin =< 1.5 x upper limit of normal for age

- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135
and serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST])
=< 3 x upper limit of normal (note that for ALT, the upper limit of normal is defined
as 45 U/L)

- Sinusoidal obstruction syndrome (SOS) if present, must be stable or improving
clinically

- Cardiac function:

- Normal ejection fraction (>= 55%) documented by either echocardiogram or
radionuclide multi gated acquisition scan (MUGA) evaluation; OR

- Normal fractional shortening (>= 27%) documented by echocardiogram

- No dyspnea at rest

- Serum triglyceride =< 300 mg/dL (applicable only for dose levels that include
isotretinoin) (note that a non-fasting triglyceride value could be obtained, if this
is > 300 mg/dL then a fasting triglyceride should be obtained and patient will be
eligible if the fasting level is =< 300 mg/dL)

- =< grade 2 hypercalcemia (applicable only for dose levels that include cis retinoic
acid [RA])

- Skin toxicity =< grade 1

- All post-menarchal females must have a negative beta-human chorionic gonadotropin
(HCG); males and females of reproductive age and childbearing potential must use
effective contraception for the duration of their participation; females of
childbearing potential (FCBP) must have a negative serum or urine pregnancy test with
a sensitivity of at least 25 mIU/mL within 10-14 days and again within 24 hours prior
to prescribing lenalidomide for cycle 1 and must either commit to continued abstinence
from heterosexual intercourse or begin TWO acceptable methods of birth control, one
highly effective method and one additional effective method AT THE SAME TIME, at least
28 days before she starts taking lenalidomide; FCBP must also agree to ongoing
pregnancy testing; men must agree to use a latex condom during sexual contact with a
FCBP even if they have had a successful vasectomy

- Patients with other ongoing serious medical issues must be approved by the study chair
prior to registration

Exclusion Criteria:

- Quantitative serum b-HCG must be negative in girls who are post-menarchal; males or
females of reproductive potential may not participate unless they have agreed to use
an effective contraceptive method; pregnant or breast-feeding women will not be
entered on this study

- Breast feeding women are not eligible

- Patients who have an active or uncontrolled infection are excluded

- Patients with a paraben allergy cannot take isotretinoin preparations containing this
compound (i.e. Accutane, Sotret) but are eligible if they can take an alternate
preparation without paraben; (applicable only for entry onto dose levels receiving
isotretinoin)

- Patients with a history of venous or arterial thrombosis personally before the age of
40 years unless associated with a central line

- Patients with a history of prior central nervous system (CNS) metastases or skull
lesions with intracranial extension will be required to have a head computed
tomography (CT) or magnetic resonance imaging (MRI) at study entry demonstrating no
active CNS metastases; patients with skull metastases with associated intracranial
soft tissue masses will remain eligible

- Inability to swallow lenalidomide capsules whole; capsules of 13-isotretinoin may be
opened

- Patient declines participation in NANT 2004-05; unless the institution has been
granted special exemption from mandatory enrollment on NANT 2004-05 by the NANT
Operations Center
We found this trial at
15
sites
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Principal Investigator: Suzanne Shusterman
Phone: 617-632-4901
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
5721 S. Maryland Avenue
Chicago, Illinois 60637
Principal Investigator: Susan L. Cohn
Phone: 773-702-2571
?
mi
from
Chicago, IL
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Principal Investigator: Brian D. Weiss
Phone: 513-636-9863
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Principal Investigator: Araz Marachelian
Phone: 323-361-8573
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Yael P. Mosse
Phone: 215-590-0965
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
1540 East Hospital Drive
Ann Arbor, Michigan 48109
(877) 475-6688
Principal Investigator: Gregory A. Yanik
Phone: 734-746-3243
C S Mott Children's Hospital Behind the doors of C.S. Mott Children's Hospital there exist...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Kelly C. Goldsmith
Phone: 404-727-2655
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Margaret E. Macy
Phone: 720-777-8856
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
801 7th Avenue
Fort Worth, Texas 76104
(682) 885-4000
Principal Investigator: Mary Meaghan P. Granger
Phone: 682-885-4007
Cook Children's Medical Center Cook Children's Health Care System is a not-for-profit, nationally recognized pediatric...
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
725 Welch Rd
Palo Alto, California 94304
(650) 497-8000
Principal Investigator: Neyssa M. Marina
Phone: 650-723-5535
Lucile Packard Children's Hospital Stanford University Stanford Children's Health is the only network in the...
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Katherine K. Matthay
Phone: 415-476-0603
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
4800 Sand Point Way NE
Seattle, Washington 98105
(206) 987-2000
Principal Investigator: Julie R. Park
Phone: 206-987-1947
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
555 University Avenue
Toronto, Ontario M5G 1X8
Principal Investigator: Sylvain Baruchel
Phone: 416-813-7795
?
mi
from
Toronto,
Click here to add this to my saved trials